Healthcare

Modular Medical Completes Pivot Patient Research Study with Thrivable

Modular Medical has completed a three-phase patient research study with Thrivable examining treatment burden, insulin pump adoption barriers and perceptions of its Pivot tubeless patch pump.

Published:
Reading Time
3 min

Modular Medical, Inc. (NASDAQ:MODD) has completed a three-phase market research study with Thrivable examining treatment burden, barriers to insulin pump adoption and perceptions of the company’s Pivot™ tubeless patch pump. More than 540 people with Type 1 and Type 2 diabetes participated in the research.

#Study examined treatment burden and pump adoption

The research included people using multiple daily injections (MDI) as well as participants who had moved to insulin pump therapy. The first phase involved over 230 participants who reviewed introductory Pivot materials and answered questions about treatment burden, adoption barriers and interest in a simplified patch pump.

A group of 20 participants then took part in 45-minute interviews. This group included people who had not used a pump, former pump users who had returned to injections and current pump users. The interviews explored participants’ decision-making, motivations and initial responses to Pivot.

The final phase surveyed more than 300 MDI users about product messaging, educational needs and factors that could encourage consideration of insulin pump therapy. The study also grouped respondents into high-, moderate- and low-burden categories based on four treatment-burden questions.

#Interest in simpler insulin delivery

Approximately nine out of 10 MDI users said they would consider a simpler way to deliver insulin. Among participants classified as highly burdened, 82.8% said they would discuss Pivot with a healthcare provider. The corresponding figure for low-burden participants was 64.8%.

In the final phase, 48.5% of participants (N=303) expressed strong interest in Pivot. The company said the findings showed that treatment burden remains an issue for people managing diabetes with multiple daily injections.

#Cost, effort and provider recommendations

Among pump-naïve participants, 41.8% identified the absence of a healthcare provider recommendation as their main reason for not adopting pump therapy.

Across more than 300 survey participants, lower cost was cited by 59.7% as an important factor in considering another insulin delivery method, while reduced effort was cited by 57.4%.

Among current pump users who had previously used injections, better glucose control was cited by 48.0% as a reason for switching. A further 44.0% said they had become tired of multiple daily injections.

#Information needs and Type 1 and Type 2 responses

Participants indicated that practical information about using a patch pump was important. The most frequently cited information need, reported by 54.1%, was how securely the device remains attached during daily activities.

The study reported different levels of interest between Type 1 and Type 2 respondents. Before detailed product messaging in the first phase, 85.1% of Type 2 respondents expressed strong interest, compared with 53.6% of Type 1 respondents. In the broader survey, 57.8% of Type 2 respondents and 38.9% of Type 1 respondents reported favourable perceptions of Pivot.

#Company plans and study limitations

Jeb Besser, Modular Medical’s Chief Executive Officer, said the findings would inform patient engagement, educational initiatives and commercialisation planning as the company prepares for the full commercial launch of Pivot.

Modular Medical said the research was based on self-reported responses from a limited number of participants. The company cautioned that the results may not represent the broader patient population or predict actual patient adoption, healthcare provider recommendations or purchasing behaviour.

The company also identified risks related to executing the full commercial launch, market acceptance, manufacturing products at high volumes and general economic, industry or political conditions. Modular Medical describes Pivot as a tubeless patch pump designed for people requiring intensive insulin therapy.

#Key Takeaways

  • More than 540 people with Type 1 and Type 2 diabetes took part in Modular Medical’s three-phase study with Thrivable.
  • Approximately nine out of 10 MDI users said they would consider a simpler insulin delivery option.
  • Among highly burdened participants, 82.8% said they would discuss Pivot with a healthcare provider.
  • Lower cost and reduced effort were cited by 59.7% and 57.4% of survey participants, respectively, as factors supporting consideration of another delivery method.
  • Modular Medical said the self-reported findings may not represent the broader patient population or predict actual adoption or purchasing behaviour.

Original source: Read original article

Frequently Asked Questions